Mercer Global Advisors Inc Summit Therapeutics Inc. Transaction History
Mercer Global Advisors Inc
- $48.3 Billion
- Q2 2025
A detailed history of Mercer Global Advisors Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 36,452 shares of SMMT stock, worth $682,016. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,452
Previous 37,395
2.52%
Holding current value
$682,016
Previous $721,000
7.49%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SMMT
# of Institutions
271Shares Held
90.9MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$631 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$162 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$75.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$73.1 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...